RxDoctor Payments Data

Deepika Abbadi, MD

Cardiovascular Disease · Des Moines, IANPI 1205191210

Payments from drug & device makers

$1,817in general payments, 2019–2025

Across 121 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$712
  • Astellas Pharma US Inc$406
  • Novartis$258
  • Johnson & Johnson$105
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$103
  • Abbott$48
  • plus $186 from 9 others

What the payments were for

  • Food & beverage$1,39777%
  • Education$42023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,817 in reported general payments places this provider in the 55th percentile of 142 cardiovascular disease providers in Iowa.

See all cardiovascular disease providers in Iowa

Medicare billing

Part B allowed, 2024
$124,519
Medicare patients
947
Services billed
2,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban457$413,724
XareltoRivaroxaban222$189,120
EntrestoSacubitril/Valsartan99$99,321
Repatha SureclickEvolocumab127$71,170
JardianceEmpagliflozin85$58,206
Praluent PenAlirocumab33$16,623
FarxigaDapagliflozin Propanediol17$13,378
Metoprolol Succinate580$6,417
Bumetanide137$4,241
Diltiazem 24hr Er (Cd)Diltiazem Hcl213$4,061
Ranolazine ErRanolazine48$4,018
PradaxaDabigatran Etexilate Mesylate16$3,624
Atorvastatin Calcium449$3,168
Flecainide Acetate50$1,975
Isosorbide Mononitrate ErIsosorbide Mononitrate125$1,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$413,724457 claims
Johnson & JohnsonXarelto$105$189,120222 claims
NovartisEntresto$258$99,32199 claims
AstraZenecaFarxiga$28$13,37817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 142 cardiovascular disease providers in Iowa.

Other cardiovascular disease in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →